Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | PTPRB | P23467 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7746218 | 0.81 | PKM (0.43) | DGAT1CA2CA12CA14TDP1 | |
| SCHEMBL7494258 | 0.81 | PKM (0.43) | DGAT1CA2CA12CA14TDP1 | |
| SCHEMBL1100241 | 0.81 | MEN1 (0.38) | DGAT1CA2CA12CA14TDP1 | |
| SCHEMBL22577405 | 0.81 | MEN1 (0.38) | DGAT1CA2CA12CA14TDP1 | |
| SCHEMBL1374814 | 0.78 | DGAT1 (0.52) | DGAT1CA2CA12CA14TDP1 | |
| SCHEMBL30202063 | 0.78 | TDP1 (0.39) | DGAT1CA2CA12CA14TDP1 | |
| SCHEMBL29958680 | 0.77 | DGAT1 (0.50) | DGAT1CA2CA12CA14TDP1 | |
| SCHEMBL28749889 | 0.76 | DGAT1 (0.45) | DGAT1CA2CA12CA14TDP1 | |
| SCHEMBL28686649 | 0.76 | DGAT1 (0.41) | DGAT1CA2CA12CA14TDP1 | |
| SCHEMBL28704683 | 0.76 | DGAT1 (0.41) | DGAT1CA2CA12CA14TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1754705-A2 | Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders | Genentech, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1063982-B1 | ANTAGONISTS FOR TREATMENT OF CD11/CD18 ADHESION RECEPTOR MEDIATED DISORDERS | GENENTECH INC (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20050148588-A1 | LFA-1 antagonist compounds | GENENTECH, INC. | 2005-07-07 | — | — | US | disclosed |
| US-6872735-B2 | LFA-1 antagonist compounds | GENENTECH, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| US-6667318-B2 | Antiinflammatory agents; autoimmune disease | GENENTECH, INC. | 2003-12-23 | — | — | US | disclosed |
| US-20020119994-A1 | LFA-1 Antagonist compounds | GENENTECH, INC | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119994-A1 | LFA-1 Antagonist compounds | ICAM1, VCAM1, CD58 | DGAT1 3980/4885CA2 3393/4885CA12 3589/4885 |
| US-20050148588-A1 | LFA-1 antagonist compounds | CD58, VCAM1, ICAM1 | DGAT1 3514/4885CA2 3748/4885CA12 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.